Arcus Biosciences (NYSE:RCUS) CAO Alexander Azoy Sells 2,562 Shares

Arcus Biosciences, Inc. (NYSE:RCUS) CAO Alexander Azoy sold 2,562 shares of the stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $25.77, for a total transaction of $66,022.74. Following the completion of the transaction, the chief accounting officer owned 39,581 shares in the company, valued at $1,020,002.37. The trade was a 6.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Arcus Biosciences Stock Performance

Shares of NYSE RCUS opened at $25.74 on Tuesday. The firm has a fifty day moving average price of $23.61 and a 200-day moving average price of $22.73. The company has a debt-to-equity ratio of 0.19, a current ratio of 4.04 and a quick ratio of 4.04. The stock has a market cap of $3.24 billion, a PE ratio of -8.10 and a beta of 0.87. Arcus Biosciences, Inc. has a 1 year low of $7.91 and a 1 year high of $28.72.

Arcus Biosciences (NYSE:RCUS) last announced its quarterly earnings data on Tuesday, May 5th. The company reported ($1.02) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.10). The firm had revenue of $17.00 million during the quarter, compared to analysts’ expectations of $29.49 million. Arcus Biosciences had a negative return on equity of 68.97% and a negative net margin of 156.36%.The business’s revenue for the quarter was down 39.3% on a year-over-year basis. During the same period last year, the company earned ($1.14) earnings per share. Equities analysts anticipate that Arcus Biosciences, Inc. will post -3.54 earnings per share for the current fiscal year.

Institutional Trading of Arcus Biosciences

Institutional investors and hedge funds have recently bought and sold shares of the business. Hantz Financial Services Inc. lifted its stake in Arcus Biosciences by 121.9% during the 4th quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $38,000 after acquiring an additional 881 shares during the period. SBI Securities Co. Ltd. raised its position in Arcus Biosciences by 13,547.6% during the third quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock worth $39,000 after acquiring an additional 2,845 shares during the period. T. Rowe Price Investment Management Inc. acquired a new stake in shares of Arcus Biosciences in the fourth quarter valued at about $39,000. KBC Group NV acquired a new stake in shares of Arcus Biosciences in the first quarter valued at about $50,000. Finally, Strs Ohio acquired a new stake in shares of Arcus Biosciences in the first quarter valued at about $67,000. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

RCUS has been the subject of several research reports. Leerink Partners set a $47.00 price objective on shares of Arcus Biosciences in a research report on Monday, April 20th. The Goldman Sachs Group raised their target price on shares of Arcus Biosciences from $30.00 to $34.00 and gave the stock a “buy” rating in a report on Thursday, May 7th. Wall Street Zen lowered shares of Arcus Biosciences from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. Wedbush lifted their price objective on shares of Arcus Biosciences from $37.00 to $41.00 and gave the company an “outperform” rating in a report on Thursday, April 2nd. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Arcus Biosciences in a research report on Monday, April 20th. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $33.89.

Arcus Biosciences Company Profile

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.